<SEC-DOCUMENT>0000950103-18-013228.txt : 20181108
<SEC-HEADER>0000950103-18-013228.hdr.sgml : 20181108
<ACCEPTANCE-DATETIME>20181108085251
ACCESSION NUMBER:		0000950103-18-013228
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181108
FILED AS OF DATE:		20181108
DATE AS OF CHANGE:		20181108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		181168349

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp98168_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">SECURITIES AND EXCHANGE
COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0pt; text-indent: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; margin: 0pt; width: 15%; text-indent: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0pt; text-indent: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; margin: 0pt; width: 15%; text-indent: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">Report
of Foreign Private Issuer</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">Pursuant to Rule 13a-16 or 15d-16 of</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">the Securities Exchange Act of 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">November
8, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">Commission
File Number: 001-38283</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0pt; text-indent: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; margin: 0pt; width: 25%; text-indent: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>InflaRx N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0pt; text-indent: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; margin: 0pt; width: 25%; text-indent: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>Winzerlaer Str. 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>07745 Jena, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>(+49) 3641 508180</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">(Address of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin: 0pt; text-indent: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; margin: 0pt; width: 25%; text-indent: 0pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">Form 20-F <FONT STYLE="font-family: Wingdings">x
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 2pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">INFLARX N.V.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 6pt">On November 8, 2018, InflaRx N.V. issued a press
release titled &ldquo;InflaRx Completes Enrollment of Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 6pt">A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.05pt 0pt 6pt; text-indent: 15.15pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Jena, Germany, November 8, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: left; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">INFLARX N.V.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-right: 2pt; padding-left: 10pt; text-indent: 0pt">By:</TD>
    <TD COLSPAN="2" STYLE="text-align: left; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt; border-bottom: Black 1pt solid">/s/ Niels Riedemann</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">Name:</TD>
    <TD STYLE="width: 41%; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">Niels Riedemann</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">Title:</TD>
    <TD STYLE="padding-right: 2pt; padding-left: 2pt; text-indent: 0pt">Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</FONT></TD>
    <TD STYLE="width: 89%; border-bottom: black 1pt solid; padding-right: 2pt; padding-left: 2pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Exhibit</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 2pt; padding-left: 2pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-right: 2pt; padding-left: 2pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated November 8, 2018. </FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp98168_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Arial, Helvetica, Sans-Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="image_001.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">InflaRx Completes Enrollment in Phase IIb
Clinical Trial<BR>
with Lead Candidate IFX-1 in Hidradenitis Suppurativa</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">Trial Results Anticipated First Half 2019</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Jena, Germany, November 08, 2018
&ndash; InflaRx N.V. </B><FONT STYLE="font-size: 10pt">(</FONT>Nasdaq:<FONT STYLE="font-size: 10pt">IFRX)</FONT>, a
biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the
complement system, a key component of the innate immune system, today announced that patient enrollment has been completed in
the phase IIb study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a
antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS). HS is a painful and debilitating
chronic inflammatory skin disease with limited treatment options.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">The randomized, double-blind, placebo-controlled,
multicenter study is being conducted at 38 sites in both North America and Europe. Following a placebo-controlled, double-blind
period of 16 weeks investigating four different IFX-1 dosing arms plus one placebo arm, there is a 28-week open-label extension
phase to assess long-term efficacy and safety. The primary endpoint is dose response signal, assessed by the Hidradenitis Suppurativa
Clinical Response (HiSCR) score, at week 16. Additional objectives include the evaluation of safety and tolerability of IFX-1,
as well as an assessment of additional efficacy and patient-reported outcome parameters. Topline results from the trial are expected
in the first half of 2019.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Othmar Zenker, M.D., Chief Medical Officer
of InflaRx, said: &ldquo;We are very pleased to have completed enrollment in this Phase IIb trial within our stated timeframe.
Following the promising results we observed in our earlier trial with IFX-1 in Hidradenitis Suppurativa, our goal with this phase
IIb study is to determine the optimal dose regimen, as well as assess both long-term efficacy and safety of IFX-1 in patients with
this disease.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Prof. Dr. med. Evangelos J. Giamarellos-Bourboulis,
of the ATTIKON University Hospital in Athens, Greece, the principal investigator of this trial, said: &ldquo;Hidradenitis Suppurativa
is a debilitating, painful and frequently life-long disease. For patients with moderate to severe HS, treatment options are limited,
and there is an urgent need to find more effective therapies. The C5a blockade with IFX-1 offers an entirely new mode of action
to tackle this disease, and I look forward to seeing the results from this study.&rdquo;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About IFX-1:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">IFX-1 is a first-in-class monoclonal anti-complement
factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards
its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism,
which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response
driven tissue and organ damage by specifically blocking C5a as a key &ldquo;amplifier&rdquo; of this response in pre-clinical studies.
IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, successfully completed three
clinical phase II studies. Until today, more than 150 people have been treated with IFX-1 within completed clinical trials, which
was well tolerated. IFX-1 is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa
and ANCA-associated vasculitis.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>About InflaRx N.V.:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">InflaRx (Nasdaq:<FONT STYLE="font-size: 10pt">IFRX)</FONT>
is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class,
potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide
variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in
Jena and Munich, Germany as well as Ann Arbor, Michigan.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Contacts:</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>InflaRx N.V.&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Jordan Silverstein&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Head of Corporate Development and Strategy&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Jordan.silverstein[at]inflarx.de&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">+1-917-837-1709</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>Media Relations&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>MC Services AG&nbsp;</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">Katja Arnold, Laurie Doyle, Andreas Jungfer&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">inflarx[at]mc-services.eu&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">+49-89-210 2280</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">FORWARD LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking
statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by
terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue&rdquo; and similar expressions. Forward-looking
statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections,
outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and
clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our
product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical
trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described
under the heading &ldquo;Risk Factors&rdquo; in InflaRx&rsquo;s periodic filings with the Securities and Exchange Commission. These
statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you
should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as required by law.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 100%; font-size: 11pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O )<# 2(  A$! Q$!_\0
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M<EBT;7CQ@C^ZGR?R6O3;SX]65OH_V;1M$N$N$C$<+73KL3 P"0I)./3BO-/
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30JT;_P 2D'T.:O44 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
